Lymphoid-specific high-efficiency beta-catenin protein degradation
- Institution
- Yale University, CT
- Principal investigator
- Markus Müschen
- Funding
- $3.1M
- Duration
- 2025–2029
Moonbase score
Still being scored
Abstract
ABSTRACT As part of canonical WNT signaling, beta-catenin forms activating transcriptional complexes with TCF7 factors to promote MYC-expression and proliferation in epithelial, neuronal, endothelial and mesenchymal cells. Despite its critical role in multiple organ systems, beta-catenin is dispensable for normal lymphopoiesis. While other cell types depend on beta-catenin to promote MYC-expression and proliferation, we discovered that B-lymphoid cells have evolved and critically depend on a previously unrecognized mechanism for high-efficiency beta-catenin protein degradation. beta-catenin mRNA levels in B-lymphoid cells were comparable to other cell types, however, beta- catenin protein levels were 80- to 200-fold lower and often undetectable. Lymphoid-specific high-efficiency beta-catenin protein degradation depends on concerted activity of the GSK3B and CK1a kinases, NEDD8-activating enzyme NAE1, and the immunoproteasome subunits PSMB8 and PSMB9. Inhibition or genetic haploinsufficiency of any of these components, reduced degradation efficiency, resulting in beta-catenin accumulation and acute cell death of B-lymphoid cells. In contrast to activating beta-catenin:TCF7 complexes that promote MYC-expression in other cell types, our studies in B-cells revealed repressive beta-catenin complexes with lymphoid Ikaros factors that induced transcriptional repression of MYC and acute cell death. We propose three Aims to (1) elucidate the mechanistic basis of high-efficiency beta-catenin protein degradation in B-lymphoid cells, (2) B-cell-specific composition and function of repressive beta-catenin complexes and (3) to develop concepts for therapeutic intervention at the level of GSK3B, CK1a, NAE1 and PSMB8 to disrupt beta- catenin protein degradation in B-cell autoimmune and lymphoproliferative conditions.
LOADING MOONBASE SCORE
Questions for Yale University
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Yale UniversityNot yet scored
Targeting GSK3B in refractory B-cell malignancies
Markus Müschen · $612K · 2023–2028
- NIH · Yale UniversityNot yet scored
SYK and ZAP70 kinases in lymphocyte selection
Eric Meffre · $599K · 2022–2027
- NIH · Yale UniversityNot yet scored
Metabolic gatekeepers in B-cell malignancies
Markus Müschen · $1.0M · 2016–2028